The company designed LOBO (low-profile braided occluder) to provide controlled mechanical occlusion of peripheral vessels. It works across a broad range of anatomies. The ALPHA Registry evaluates LOBO in patients with a variety of peripheral vascular conditions. Those include arterial hemorrhage and pulmonary arteriovenous malformation, according to the Aliso Viejo, California-based company.
Dr. Ningcheng “Peter” Li and Dr. Neil J. Resnick enrolled the first patient at UMass Memorial Medical Center.
“This case demonstrates the utility of the LOBO system in pulmonary arteriovenous malformation (PAVM) treatment. Multiple PAVMs were treated with LOBO, with one device implanted per feeding artery, and intraprocedural occlusion achieved in under two minutes per vessel,” Li and Resnick said. “This significant milestone kickstarts a substantial effort to generate meaningful clinical evidence supporting the LOBO device.”
Okami developed LOBO using its proprietary HDBraid construction to optimize deliverability, occlusivity and stability. This enables physicians to quickly achieve reliable occlusion while maintaining procedural efficiency.
The company said ALPHA marks a key step in its broader clinical strategy to provide real-world evidence for LOBO. It expects to enroll up to 500 patients across up to 30 sites. Dr. Nima Kokabi, site investigator at UNC Health System, expects ALPHA to help enhance patient care in embolization. Kokabi said the registry’s unique structure enables the assessment of distinct outcomes across multiple conditions.
This marks a significant milestone for the company after appointing former Inari Medical CEO Bill Hykes as its CEO last year. It also raised $45 million then, adding to $32.5 million raised in 2024.
